ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis
NASDAQ:ADMA - Nasdaq - US0008991046 - Common Stock - Currency: USD
Overall ADMA gets a fundamental rating of 6 out of 10. We evaluated ADMA against 561 industry peers in the Biotechnology industry. While ADMA has a great health rating, its profitability is only average at the moment. ADMA is growing strongly while it is still valued neutral. This is a good combination! These ratings would make ADMA suitable for growth investing!
1. Profitability
1.1 Basic Checks
ADMA had positive earnings in the past year.
ADMA had a positive operating cash flow in the past year.
ADMA had negative earnings in 4 of the past 5 years.
In multiple years ADMA reported negative operating cash flow during the last 5 years.
1.2 Ratios
ADMA has a Return On Assets of 40.50%. This is amongst the best in the industry. ADMA outperforms 99.47% of its industry peers.
With an excellent Return On Equity value of 55.37%, ADMA belongs to the best of the industry, outperforming 98.93% of the companies in the same industry.
ADMA has a Return On Invested Capital of 26.28%. This is amongst the best in the industry. ADMA outperforms 98.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 40.5% | ||
| ROE | 55.37% | ||
| ROIC | 26.28% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ADMA's Profit Margin of 45.01% is amongst the best of the industry. ADMA outperforms 98.93% of its industry peers.
ADMA has a Operating Margin of 33.10%. This is amongst the best in the industry. ADMA outperforms 98.22% of its industry peers.
ADMA's Gross Margin of 52.58% is fine compared to the rest of the industry. ADMA outperforms 77.01% of its industry peers.
In the last couple of years the Gross Margin of ADMA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.1% | ||
| PM (TTM) | 45.01% | ||
| GM | 52.58% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ADMA is creating value.
The number of shares outstanding for ADMA has been increased compared to 1 year ago.
ADMA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ADMA has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 23.14 indicates that ADMA is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 23.14, ADMA belongs to the best of the industry, outperforming 94.65% of the companies in the same industry.
ADMA has a debt to FCF ratio of 0.80. This is a very positive value and a sign of high solvency as it would only need 0.80 years to pay back of all of its debts.
ADMA has a better Debt to FCF ratio (0.80) than 95.72% of its industry peers.
ADMA has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.19, ADMA is doing worse than 70.05% of the companies in the same industry.
Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | 0.8 | ||
| Altman-Z | 23.14 |
ROIC/WACC2.59
WACC10.16%
2.3 Liquidity
ADMA has a Current Ratio of 6.58. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ADMA (6.58) is better than 66.31% of its industry peers.
ADMA has a Quick Ratio of 3.36. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
ADMA has a Quick ratio (3.36) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.58 | ||
| Quick Ratio | 3.36 |
3. Growth
3.1 Past
ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 2750.00%, which is quite impressive.
The Revenue has grown by 62.23% in the past year. This is a very strong growth!
Measured over the past years, ADMA shows a very strong growth in Revenue. The Revenue has been growing by 70.84% on average per year.
EPS 1Y (TTM)2750%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
Revenue 1Y (TTM)62.23%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%40.22%
3.2 Future
The Earnings Per Share is expected to grow by 28.09% on average over the next years. This is a very strong growth
Based on estimates for the next years, ADMA will show a quite strong growth in Revenue. The Revenue will grow by 19.52% on average per year.
EPS Next Y34.64%
EPS Next 2Y40.91%
EPS Next 3Y36.86%
EPS Next 5Y28.09%
Revenue Next Year18.2%
Revenue Next 2Y23.05%
Revenue Next 3Y22.93%
Revenue Next 5Y19.52%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 37.96, ADMA can be considered very expensive at the moment.
93.23% of the companies in the same industry are more expensive than ADMA, based on the Price/Earnings ratio.
ADMA's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.03.
With a Price/Forward Earnings ratio of 20.27, ADMA is valued on the expensive side.
Based on the Price/Forward Earnings ratio, ADMA is valued cheaply inside the industry as 91.98% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.94, ADMA is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.96 | ||
| Fwd PE | 20.27 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.40% of the companies listed in the same industry.
93.76% of the companies in the same industry are more expensive than ADMA, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 53.16 | ||
| EV/EBITDA | 30.49 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ADMA may justify a higher PE ratio.
ADMA's earnings are expected to grow with 36.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.1
PEG (5Y)N/A
EPS Next 2Y40.91%
EPS Next 3Y36.86%
5. Dividend
5.1 Amount
No dividends for ADMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
20.12
-0.32 (-1.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners88.05%
Inst Owner Change2.46%
Ins Owners2.17%
Ins Owner Change1.55%
Market Cap4.80B
Analysts82
Price Target26.25 (30.47%)
Short Float %5.38%
Short Ratio3.13
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.83%
Min EPS beat(2)-31.17%
Max EPS beat(2)-8.5%
EPS beat(4)2
Avg EPS beat(4)8.19%
Min EPS beat(4)-31.17%
Max EPS beat(4)59.31%
EPS beat(8)4
Avg EPS beat(8)-15.66%
EPS beat(12)7
Avg EPS beat(12)-6.3%
EPS beat(16)10
Avg EPS beat(16)-4.09%
Revenue beat(2)1
Avg Revenue beat(2)-0.57%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)2.16%
Revenue beat(4)3
Avg Revenue beat(4)7.87%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)21.61%
Revenue beat(8)7
Avg Revenue beat(8)6.02%
Revenue beat(12)11
Avg Revenue beat(12)6.72%
Revenue beat(16)15
Avg Revenue beat(16)7.22%
PT rev (1m)1.85%
PT rev (3m)6.05%
EPS NQ rev (1m)-7.69%
EPS NQ rev (3m)0%
EPS NY rev (1m)-7.04%
EPS NY rev (3m)-4.69%
Revenue NQ rev (1m)0.14%
Revenue NQ rev (3m)5.69%
Revenue NY rev (1m)0.84%
Revenue NY rev (3m)3.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.96 | ||
| Fwd PE | 20.27 | ||
| P/S | 10.45 | ||
| P/FCF | 53.16 | ||
| P/OCF | 47.42 | ||
| P/B | 12.85 | ||
| P/tB | 12.99 | ||
| EV/EBITDA | 30.49 |
EPS(TTM)0.53
EY2.63%
EPS(NY)0.99
Fwd EY4.93%
FCF(TTM)0.38
FCFY1.88%
OCF(TTM)0.42
OCFY2.11%
SpS1.93
BVpS1.57
TBVpS1.55
PEG (NY)1.1
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 40.5% | ||
| ROE | 55.37% | ||
| ROCE | 33.26% | ||
| ROIC | 26.28% | ||
| ROICexc | 31.16% | ||
| ROICexgc | 31.49% | ||
| OM | 33.1% | ||
| PM (TTM) | 45.01% | ||
| GM | 52.58% | ||
| FCFM | 19.65% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | 0.8 | ||
| Debt/EBITDA | 0.45 | ||
| Cap/Depr | 138.39% | ||
| Cap/Sales | 2.38% | ||
| Interest Coverage | 11.85 | ||
| Cash Conversion | 63.28% | ||
| Profit Quality | 43.66% | ||
| Current Ratio | 6.58 | ||
| Quick Ratio | 3.36 | ||
| Altman-Z | 23.14 |
F-Score7
WACC10.16%
ROIC/WACC2.59
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2750%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
EPS Next Y34.64%
EPS Next 2Y40.91%
EPS Next 3Y36.86%
EPS Next 5Y28.09%
Revenue 1Y (TTM)62.23%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%40.22%
Revenue Next Year18.2%
Revenue Next 2Y23.05%
Revenue Next 3Y22.93%
Revenue Next 5Y19.52%
EBIT growth 1Y243.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year57.85%
EBIT Next 3Y39.41%
EBIT Next 5Y32.66%
FCF growth 1Y247.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y309.9%
OCF growth 3YN/A
OCF growth 5YN/A